Roche Holding AG - Bearer Shares RO

SWX: RO | ISIN: CH0012032113   12/11/2024
282,60 CHF (-1,46%)
(-1,46%)   12/11/2024

5 november 2024 · Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 · Persbericht

31 oktober 2024 · Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease · Persbericht

31 oktober 2024 · New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer · Persbericht

23 oktober 2024 · [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months · Persbericht

18 oktober 2024 · Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study · Persbericht

14 oktober 2024 · Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate · Persbericht

11 oktober 2024 · FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation · Persbericht

10 oktober 2024 · Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY · Persbericht

26 september 2024 · Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis · Persbericht

24 september 2024 · Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses · Persbericht

23 september 2024 · WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions · Persbericht

19 september 2024 · Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses · Persbericht

16 september 2024 · FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis · Persbericht

13 september 2024 · FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy · Persbericht

10 september 2024 · Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation · Persbericht

4 september 2024 · Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis · Persbericht

27 augustus 2024 · Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH · Persbericht

20 augustus 2024 · Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak · Persbericht

30 juli 2024 · European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) · Persbericht

29 juli 2024 · Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care · Persbericht

Mijn selecties